Small molecule · Agonist of 5-HT4 receptor (HTR4) · developed by Processa Pharmaceuticals
PCS12852 is an oral once-daily tablet that acts as an agonist of the 5-HT4 serotonin receptor. It is being studied in gastroparesis, a disorder of delayed stomach emptying.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05270460 | Phase 2 | Gastroparesis | Completed | PCSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastroparesis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PCSA page.
See PCSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PCSA catalysts and pipeline →